VANI — Vivani Medical Share Price
0.000.00%
Last trade - 00:00- $62.21m
- $43.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.53 | ||
| Price to Tang. Book | 3.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.37% | ||
| Return on Equity | -122.42% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Directors
- Gregg Williams CHM (62)
- Scott Dunbar CEO (64)
- Edward Randolph VOP (63)
- Stephen Okland OTH (56)
- Alexandra Larson DRC (41)
- Jonathan McGuire DRC (58)
- Dean Baker IND (78)
- Aaron Mendelsohn IND (69)
- Matthew Pfeffer IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 6th, 2023
- Public Since
- December 5th, 2014
- No. of Shareholders
- 106
- No. of Employees
- 42
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 59,242,903
- Address
- 1350 S. Loop Road, ALAMEDA, 94502
- Web
- https://vivani.com/
- Phone
- +1 4155068462
- Auditors
- BPM LLP
Upcoming Events for VANI
Similar to VANI
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Vivani Medical share price?
As of Today at 24:01 UTC, shares in Vivani Medical are trading at $1.05. This share price information is delayed by 15 minutes.
How has the Vivani Medical share price performed this year?
Shares in Vivani Medical last closed at $1.05 and the price had moved by -38.05% over the past 365 days. In terms of relative price strength the Vivani Medical share price has underperformed the S&P500 Index by -42.82% over the past year.
What are the analyst and broker recommendations for Vivani Medical?
The overall consensus recommendation for Vivani Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vivani Medical dividend yield?
Vivani Medical does not currently pay a dividend.
Does Vivani Medical pay a dividend?
Vivani Medical does not currently pay a dividend.
When does Vivani Medical next pay dividends?
Vivani Medical does not currently pay a dividend.
How do I buy Vivani Medical shares?
To buy shares in Vivani Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vivani Medical?
As of the previous close price of $1.05, shares in Vivani Medical had a market capitalisation of $62.21m.
Where are Vivani Medical shares listed?
Here are the trading details for Vivani Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VANI
What kind of share is Vivani Medical?
Based on an overall assessment of its quality, value and momentum Vivani Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vivani Medical share price forecast for 2025?
The analyst consensus target price for shares in Vivani Medical is $5.00. That is 376.19% above the last closing price of $1.05.
Analysts covering Vivani Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.40 for the next financial year.
Find out moreWhat is the trend in the Vivani Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vivani Medical. Over the past six months, its share price has underperformed the S&P500 Index by -12.17%.
As of the last closing price of $1.05, shares in Vivani Medical were trading -12.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vivani Medical PE Ratio?
The Vivani Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vivani Medical?
Vivani Medical's management team is headed by:
- Gregg Williams - CHM
- Scott Dunbar - CEO
- Edward Randolph - VOP
- Stephen Okland - OTH
- Alexandra Larson - DRC
- Jonathan McGuire - DRC
- Dean Baker - IND
- Aaron Mendelsohn - IND
- Matthew Pfeffer - IND